ValueAct reports 19.3% ownership interest in Valeant Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., May 18 - Investors led by ValueAct Master Fund, LP bought 56,264 shares of Valeant Pharmaceuticals International on May 15 priced from $19.75 to $19.89 each, according to a schedule 13D/A filed on Monday with the Securities and Exchange Commission.

Between May 7 and My 14, ValueAct bought 2,535,639 shares of the company's stock, a prior SEC filing said.

The investors beneficially own 15,833,193 shares or 19.3% the Costa Mesa, Calif., specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.